Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC

Brief description of study

The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer. We want to know how the drugs work and what is the best combination dose for the treatment of Non-Small Cell Lung Cancer.


Clinical Study Identifier: s20-00901
ClinicalTrials.gov Identifier: NCT04077463


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.